IMMUcan, an integrated European immuno-oncology profiling platform
Immune checkpoint inhibitors have shown promising results in some cancer types, but biomarkers to select patients that might respond to the treatment are still missing. Similarly, rationales for combining immune checkpoint inhibitors with conventional therapy or targeted agents are lacking.
The goal of IMMUcan is to understand, how the immune system and tumours interact, and the impact of therapeutic interventions
Latest news
NEW – the IMMUcan CIMT eTalk is now available to view
On 10-12 May 2021, the IMMUcan consortium presented an [...]
An Interview with Daniel Schulz on the AACR 2021 IMMUcan Poster
This year, the American Association for Cancer Research (AACR) Annual Meeting [...]
The single cell pathology landscape of breast cancer
This is a very interesting article highly relevant for [...]
Many opportunities for collaboration!
What are the benefits for clinicians?
| 01. |
Access to the molecular results from all analyses performed on your patients. |
| 02. |
Participate in molecular tumour boards to discuss the best treatments for your patients. |
| 03. |
Opportunities to engage in IMMUcan scientific activities including possibility to publish. |
| 04. |
All costs for sample shipment and analysis are covered by IMMUcan. |
International consortium of world-class research organisations
 |
 |
 |
The IMMUcan project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821558.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.